Colfax

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Colfax (CFX) is likely to gain from opportunities in fabrication technology and orthopedic solutions businesses, buyouts, and emerging market exposure. High costs, huge debts and forex woes are dragging.

Here's Why it is Worth Holding on to Colfax (CFX) Stock Now

Colfax's (CFX) Air & Gas Handling divestment will help it pay down debts as well as concentrate on core and profitable businesses.

Colfax Completes Divestment of Air & Gas Handling Business

Annapolis Junction, MD, Sept.  30, 2019  (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax”) (NYSE: CFX), a leading diversified industrial technology company, today announced it completed the sale of its Air & Gas Handling business to an affiliate of KPS Capital Partners, LP for an aggregate consideration of $1.8 billion. The cash proceeds, net of transaction expenses and estimated taxes, of approximately $1.6 billion will be used to pay down debt. 

Colfax Completes Sale of Air & Gas Handling Business

Is Colfax Corporation (CFX) a great pick from the value investor's perspective right now? Read on to know more.

Is Colfax Corporation (CFX) a Great Pick for Value Investors?

Colfax (CFX) reported earnings 30 days ago. What's next for the stock?

Colfax (CFX) Up 0.4% Since Last Earnings Report: Can It Continue?

Colfax (CFX) is likely to benefit from its focus on strengthening segmental businesses and productivity actions, and gains from acquired assets. However, rising cost of sales is a concern.

Colfax to Gain from Strong End Markets & Buyouts Amid Risks

Colfax's (CFX) second-quarter 2019 results benefit from improvement in core sales and acquired assets. It provides projections, after adjusting for the pending divestment of the Air and Gas Handling segment.

Colfax (CFX) Q2 Earnings Top Estimates, Sales Gain on Buyouts

Colfax Corporation's (CFX) CEO Matthew Trerotola on Q2 2019 Results - Earnings Call Transcript

Colfax (CFX) delivered earnings and revenue surprises of 6.67% and -27.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) Beats Q2 Earnings Estimates

President & CEO of Colfax Corp (30-Year Financial, Insider Trades) Matthew L. Trerotola (insider trades) sold 18,589 shares of CFX on 07/25/2019 at an average price of $28.51 a share.

Colfax Corp (CFX) President & CEO Matthew L. Trerotola Sold $529,972 of Shares

Colfax (CFX) might suffer from high costs and operating expenses, huge debt levels, and unfavorable movements in foreign currencies.

Here's Why You Should Avoid Betting on Colfax (CFX) Stock Now

Why Is Colfax (CFX) Down 0.2% Since Last Earnings Report?

The divestiture of Air and Gas Handling business will enable Colfax (CFX) to reach its leverage target and raise profitability ratio.

Colfax (CFX) to Divest Air and Gas Handling Business to KPS

Colfax's (CFX) acquisition of DJO Global marks its entry into the orthopedic solutions industry. High debts and forex woes remain concerning.

Colfax (CFX) Poised to Gain From Buyouts, Suffers From Debts

Colfax came in a little soft on revenue, but segment profits were a little better than expected and the DJO business got off to a decent start under Colfax.

Colfax Logs A Stable Quarter Amid Significant Transformation

Colfax's (CFX) first-quarter 2019 results benefit from gains from acquired assets, especially DJO Global as well as improvement in existing businesses and margins.

Colfax (CFX) Q1 Earnings Top Estimates, Gain From Buyouts

Colfax Corporation's (CFX) CEO Matt Trerotola on Q1 2019 Results - Earnings Call Transcript

Colfax (CFX) delivered earnings and revenue surprises of 8.16% and -2.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) Q1 Earnings Surpass Estimates

Colfax (CFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Colfax (CFX) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Colfax (CFX) Could Beat Earnings Estimates Again

Let's see if Colfax (CFX) stock is a good choice for value-oriented investors right now from multiple angles.

Is Colfax (CFX) a Suitable Stock for Value Investors Now?

With this article, I would like to introduce to my SA readers a stock that might meet their criteria for being an excellent investment opportunity.

News for Colfax Stock (CFX)